Lv51
830 积分 2024-03-25 加入
Discovery of BMS-986458, a Potent and Selective B-Cell Lymphoma 6 Protein Ligand-Directed Degrader, for the Treatment of B-Cell Non-Hodgkin Lymphoma
13天前
已完结
Early Process Development of a Heterobifunctional Protein Degrader
1个月前
已完结
Discovery of CFT8634, a Potent, Selective, and Orally Bioavailable Heterobifunctional Degrader of BRD9
1个月前
已完结
Lessons learned in linking PROTACs from discovery to the clinic
1个月前
已完结
Lead Optimization of Small Molecule ENL YEATS Inhibitors to Enable In Vivo Studies: Discovery of TDI-11055
1个月前
已完结
Design, synthesis of novel benzimidazole derivatives as ENL inhibitors suppressing leukemia cells viability via downregulating the expression of MYC
2个月前
已完结
Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches
2个月前
已完结
Allosteric inhibition of JAK2 with lysine-reactive compounds that bind the pseudokinase domain
2个月前
已完结
Next-Generation JAK Inhibitors in the Treatment of Myeloproliferative Neoplasms
2个月前
已关闭
The enigma of KMT2A gene in hematological disorders
4个月前
已完结
皖公网安备34019202002308
